Europe will become the next market for Aurobindo

[chinapharma.com Enterprise News] Indian pharmaceutical companies have traditionally attached great importance to API production and preparation production Therefore, Aurobindo hopes to improve the operation efficiency and cost of supply chain and distribution, so as to increase cooperation opportunities globally In traditional emerging markets such as China, South Africa and Russia, Aurobindo is committed to building brand generic products and deepening market penetration and occupancy through local production (Europe will become the next market opening up of Aurobindo, an Indian imitated pharmaceutical company Picture source: Baidu picture) Aurobindo, located in Hyderabad, is an Indian Multinational Pharmaceutical Company Most of the time, the company is thinking about it What's the next market with growth potential? Although Aurobindo still focuses on the United States, the world's largest pharmaceutical market and all of India's major export markets, in the next three to four years, Aurobindo will gradually turn its attention to Europe, the company told investors At present, the generic drug company is actively expanding opportunities in EU countries such as Poland and the Czech Republic Eastern European countries can be described as the emerging market of Indian drug companies At the same time, the generic business is growing in other European countries, the company said "Generic penetration is generally low in Italy, Spain, Portugal and France, which will provide potential for future growth as the share of generic will improve." The European plan will focus on cancer treatment and injection products, the company added It is necessary to carry out this plan in a short time without acquisition Aurobindo has acquired generis fariceutica SA and has integrated the company as an important step in the Portuguese generic market, providing value chain and Production assurance In addition, Aurobindo acquired the orocal brand, increasing its share and role in the French market Of course, this plan is not to abandon the United States completely In fact, the United States is still the main market of Aurobindo, but the focus is different In the United States, the company is mainly looking to accelerate its focus on injection, over-the-counter (OTC) and highly complex generic product portfolios Indian pharmaceutical companies have traditionally focused on API production and pharmaceutical production, so Aurobindo wants to improve the operational efficiency and cost of supply chain and distribution so as to increase opportunities for cooperation globally In traditional emerging markets such as China, South Africa and Russia, the company is committed to building brand generic products and deepening market penetration and occupancy through local production The plan calls for increased investment in specific treatment areas, especially anti-tumor and special injections.